7
Nov
2021
Aspiring Healthtech Companies Require A Nuanced Understanding Of Healthcare’s Human Dynamics
The best concise summary I’ve seen of tech industry travails in healthcare comes from Blake Dodge, a reporter at Business Insider. Dodge had just written a piece about Apple Health, and took to LinkedIn to share an additional quote that didn’t quite make the final copy. “I think they came to it pure of heart, really thinking that they could... Read More
4
Nov
2021
The Vaccine Pile-Up, Regeneron Crushes It, CF Foundation Bets on Flagship Combos
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Nov
2021
CF Foundation Invests up to $110M in Flagship Unit to Combine Technologies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Oct
2021
Pfizer Vaccine OK’d for Kids, Merck Ensures Global Access, and Maraganore Passes Torch
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Oct
2021
Young Biotech Entrepreneurs Finding Community: Tony Kulesa on The Long Run
Today’s guest on The Long Run is Tony Kulesa. Tony is the co-founder of Boston-based Petri. It’s a seed and pre-seed investor in biotech startups. But that doesn’t quite fully describe it. It’s also a community for young founders trying to figure out how to get new enterprises off the ground, and connected with a network of seasoned entrepreneurs who... Read More
26
Oct
2021
DNA Script Snags $165M to Build Up Benchtop DNA Synthesis Market, Technology
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Oct
2021
Biogen’s Face-plant, an Interchangeable Humira, & Boosters OK’d
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Oct
2021
ADCs: If at First You Don’t Succeed…
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Oct
2021
Califf Back at FDA? Moderna’s Booster Slam Dunk, & the Vaccine Equity Debate
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Oct
2021
5 Themes to Track at ASHG 2021
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Oct
2021
Reimagining DNA Sequencing With Long Reads: Christian Henry on The Long Run
Today’s guest on The Long Run is Christian Henry. Christian is the CEO of Menlo Park, Calif.-based PacBio. It makes DNA sequencing instruments that are used by scientists around the world. The company has long toiled in the shadow of the market leader – some would say monopolist in DNA Sequencing – Illumina. PacBio was way overhyped in its early... Read More
7
Oct
2021
Collins Exits NIH; WHO Backs GSK Malaria Vaccine; RA, MPM, Atlas Reload
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Oct
2021
Neumora Secures $500M, Amgen Deal, in Quest for Precision Neuroscience R&D
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Oct
2021
RNA 2.0 Startups Take Aim at Improved Delivery, Target Specificity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Oct
2021
Exo Pockets $78M to Make Small Molecules Against Exosite Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Oct
2021
Pharma’s Digital Transformation: Enduring Challenges, Sustained Hopes, And A Progress Report From Lilly’s CEO
When it comes to emerging digital and data technologies, most pharma CEOs today are singing from the same hymnal. They all emphasize their commitment to digital transformation, and assert that the adoption of digital processes are key to their companies’ success, and vital for the industry’s future. A recent Lazard survey of healthcare leaders echoes this message. The investment bank... Read More
30
Sep
2021
Merck Buys Acceleron, Regeneron Antibody Saves Lives, & Moderna Invests in Cambridge
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Sep
2021
Expansion Snags $80M to Make Small Molecules Against RNA Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Sep
2021
Sequencing Genomes of Indigenous Populations: Keolu Fox on The Long Run
Today’s guest on The Long Run is Keolu Fox. Keolu is an assistant professor at UCSD with a fascinating mix of interests. He’s a Native Hawaiian, and got his PhD in genome sciences from the University of Washington. He’s now taking that mix of life experience and scientific training, and putting it to work on projects that sequence the DNA... Read More
23
Sep
2021
J&J Bounces Back, Illumina-Grail Scrutiny, & AZ’s HER-2 ADC Triumph
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.